Mikuláš Redecha, Karol Holomáň
Leiomyomata are benign, hormone-dependent tumours originating from the uterine smooth muscle cells of the myometrium.
For many women seeking avoidance of surgery a long-term pharmacological treatment of uterine myomas is
needed. As a suitable molecule, that meets the criteria of long-term, safe, and well acceptable treatment, seems to be
Ulipristal acetate (UPA). Currently we have data from the four consequent clinical studies – PEARL I-IV (PGL4001 (UPA)
Efficacy Assessment in Reduction of Symptoms due to Uterine Leiomyomata). The authors in the article reviewed the
results of studies PEAR III and IV with their critical evaluation. However, for the precise evaluation of the long-term
treatment of UPA, additional clinical, randomized, double-blinded studies will be required as well as clinical experience
of gynaecologists and their patients from their everyday clinical practice.